Krystal Biotech, Inc. (KRYS)Healthcare | Biotechnology | Pittsburgh, United States | NasdaqGS
351.46 USD
-6.00
(-1.679%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 351.46 |
Hot Take ↕ | Aug. 22, 2026, 4:37 a.m. EDT
Krystal Biotech demonstrates exceptional operational metrics with a fortress balance sheet and robust revenue expansion, supporting a strong long-term investment case despite a single-year price contraction in the recent annual history. The short-term outlook benefits from accelerating momentum and aggressive call positioning, though the elevated valuation and recent annual dip warrant caution. There is no dividend income available. Overall, the company's cash-rich status and high margins justify a premium entry for investors seeking growth, while the options market's heavy put writing at lower strikes acts as a necessary hedge against the inherent biotech volatility. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.087693 |
| MSTL | 0.153672 |
| AutoETS | 0.154117 |
| AutoARIMA | 0.154118 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 0.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.386 |
| Excess Kurtosis | -1.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.651 |
| Revenue per Share | 15.076 |
| Market Cap | 10,402,806,784 |
| Trailing P/E | 44.83 |
| Forward P/E | 37.40 |
| Beta | 0.54 |
| Profit Margins | 54.82% |
| Website | https://www.krystalbio.com |
As of Aug. 22, 2026, 4:37 a.m. EDT: Call volume significantly exceeds put volume, with open interest concentrated in out-of-the-money strikes across multiple expirations, signaling speculative bets on continued appreciation. Conversely, put writers have accumulated substantial open interest at lower strikes (280-310), creating a defensive floor that suggests traders anticipate potential volatility or downside protection needs amidst the rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3990605 |
| Address1 | 2,100 Wharton Street |
| Address2 | Suite 701 |
| All Time High | 382.535 |
| All Time Low | 8.03 |
| Ask | 332.34 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 224,290 |
| Average Daily Volume3 Month | 416,408 |
| Average Volume | 416,408 |
| Average Volume10Days | 224,290 |
| Beta | 0.536 |
| Bid | 352.61 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 45.923 |
| City | Pittsburgh |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 351.46 |
| Current Ratio | 8.318 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 356.92 |
| Day Low | 348.57 |
| Debt To Equity | 0.651 |
| Display Name | Krystal Biotech |
| Earnings Call Timestamp End | 1,785,760,200 |
| Earnings Call Timestamp Start | 1,785,760,200 |
| Earnings Growth | 0.388 |
| Earnings Quarterly Growth | 0.429 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | 199,292,992 |
| Ebitda Margins | 0.45244 |
| Enterprise To Ebitda | 48.0 |
| Enterprise To Revenue | 21.717 |
| Enterprise Value | 9,566,028,800 |
| Eps Current Year | 7.86507 |
| Eps Forward | 9.39768 |
| Eps Trailing Twelve Months | 7.84 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 347.9038 |
| Fifty Day Average Change | 3.5561829 |
| Fifty Day Average Change Percent | 0.010221742 |
| Fifty Two Week Change Percent | 139.90605 |
| Fifty Two Week High | 382.535 |
| Fifty Two Week High Change | -31.075012 |
| Fifty Two Week High Change Percent | -0.081234425 |
| Fifty Two Week Low | 136.73 |
| Fifty Two Week Low Change | 214.73 |
| Fifty Two Week Low Change Percent | 1.5704674 |
| Fifty Two Week Range | 136.73 - 382.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 23,568,369 |
| Forward Eps | 9.39768 |
| Forward P E | 37.39859 |
| Free Cashflow | 151,739,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 295 |
| Fullday Change | -6.0 |
| Fullday Change Percent | -1.67851 |
| Fullday Price | 351.46 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.94639 |
| Gross Profits | 416,868,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10828 |
| Held Percent Institutions | 1.02523 |
| Implied Shares Outstanding | 29,598,836 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. |
| Long Name | Krystal Biotech, Inc. |
| Market | us_market |
| Market Cap | 10,402,806,784 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_534062888 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 241,464,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,584,691,747 |
| Number Of Analyst Opinions | 8 |
| Open | 356.92 |
| Operating Cashflow | 272,337,984 |
| Operating Margins | 0.48999 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 412 586 5830 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 351.46 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 357.46 |
| Price Eps Current Year | 44.686188 |
| Price Hint | 2 |
| Price To Book | 7.6532454 |
| Price To Sales Trailing12 Months | 23.616764 |
| Profit Margins | 0.54818 |
| Quick Ratio | 7.726 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.27273 |
| Region | US |
| Regular Market Change | -6.0 |
| Regular Market Change Percent | -1.67851 |
| Regular Market Day High | 356.92 |
| Regular Market Day Low | 348.57 |
| Regular Market Day Range | 348.57 - 356.92 |
| Regular Market Open | 356.92 |
| Regular Market Previous Close | 357.46 |
| Regular Market Price | 351.46 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 143,505 |
| Return On Assets | 0.093669996 |
| Return On Equity | 0.20124 |
| Revenue Growth | 0.241 |
| Revenue Per Share | 15.076 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,598,836 |
| Shares Percent Shares Out | 0.1083 |
| Shares Short | 3,204,909 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,496,648 |
| Short Name | Krystal Biotech, Inc. |
| Short Percent Of Float | 0.17729999 |
| Short Ratio | 5.75 |
| Source Interval | 15 |
| State | PA |
| Symbol | KRYS |
| Target High Price | 474.0 |
| Target Low Price | 284.0 |
| Target Mean Price | 385.0 |
| Target Median Price | 389.0 |
| Total Cash | 845,630,976 |
| Total Cash Per Share | 28.57 |
| Total Debt | 8,853,000 |
| Total Revenue | 440,484,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 7.84 |
| Trailing P E | 44.82908 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 285.5625 |
| Two Hundred Day Average Change | 65.89749 |
| Two Hundred Day Average Change Percent | 0.23076381 |
| Type Disp | Equity |
| Volume | 143,505 |
| Website | https://www.krystalbio.com |
| Zip | 15,203 |